Compare LTC Properties Inc (LTC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Novo Nordisk A/S — how do they compare? LTC Properties Inc trades at $42.46 (market cap $2.27B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 72.8× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.42%). Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Novo Nordisk A/S for 116 Days on average.
| LTC | NVO | |
|---|---|---|
Market Cap | $2.27B | $165.31B |
Volume | 574,171 | 11,432,838 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $63.98 |
52-Week Low | $33.98 | $35.29 |
Typical Hold Time | 88 Days | 116 Days |
Enterprise Value | $3.01B | $179.56B |
Dividend Yield | 5.42% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.05, up 0.57% today, with a mixed technical picture showing bearish overall signals but bullish moving averages. The REIT demonstrates strong fundamentals with 38.93% net income margin and consistent dividend payments. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with steady income from monthly dividends and strategic SHOP portfolio expansion, though elevated debt levels and rising interest rates pose headwinds. The stock trades below analyst targets but faces execution risks in its transition to 75% SHOP NOI by 2028.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
